SCHEMBL4700716

SCHEMBL4700716

Cc1ccc2c(c1-c1ccccc1)C(=O)C(=O)N2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.48
MAOA P21397 6/20 0.47
MAOB P27338 6/20 0.47
CES1 P23141 3/20 0.47
MAPT P10636 3/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
DUSP3 P51452 1/20 0.42
BLM P54132 1/20 0.42
PTPN5 P54829 1/20 0.42
PTPN11 Q06124 1/20 0.42
MCL1 Q07820 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ROS1 P08922 1/20 0.40
CDK5 Q00535 1/20 0.40
ACVR1 Q04771 1/20 0.40
LRRK2 Q5S007 1/20 0.40
HTT P42858 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3391317 0.77 CES1 (0.67) MAOAMAOBCES1MAPTKMT2A
SCHEMBL2136384 0.76 CES1 (0.60) RETMAOAMAOBCES1POLB
SCHEMBL3743988 0.76 CES1 (0.50) MAOAMAOBCES1MAPTKMT2A
Hydrazine SCHEMBL27286479 0.75 CES1 (0.46) MAOAMAOBCES1MAPTKMT2A
SCHEMBL3531791 0.74 CES1 (0.48) MAOAMAOBCES1MAPTKMT2A
SCHEMBL22391489 0.74 MAPT (0.48) MAPTKMT2ATDP1HTTALDH1A1
SCHEMBL27453644 0.74 GSK3B (0.43) RETMAPTKMT2AMEN1POLB
SCHEMBL7827616 0.73 MAPT (0.52) MAOAMAOBCES1MAPTKMT2A
SCHEMBL9110123 0.71 MAOA (0.57) RETMAOAMAOBCES1MAPT
SCHEMBL14812709 0.69 MAOA (0.53) RETMAOAMAOBCES1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996553-A2 TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES Avanir Pharmaceuticals (US) 2008-12-03 EP disclosed
WO-2007109251-A2 TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES AVANIR PHARMACEUTICALS (US) 2007-09-27 WO disclosed